The Week in Review: August 11 – August 18, 2017

Friday, August 18, 2017 Canada Great news in Canada. Two new drug regimens have been approved:  Vosevi from Gilead is a pangenotypic for retreatment of those who have failed previous DAA therapy Gilead Receives Approval in Canada for VOSEVI™ (Sofosbuvir/Velpatasvir/Voxilaprevir) for Re-treatment of Certain Patients with Chronic Hepatitis C Virus (HCV) Infection. And MAVIRET from AbbVie is the first and only 8-week, pan-genotypic treatment for hepatit...

Hepatitis C Virus Infection and Cardiovascular Disease Risk

Patients with HCV infection have a higher risk for carotid atherosclerosis and cerebrocardiovascular events. Hepatitis C virus (HCV) infection is a common cause of chronic liver disease worldwide and is associated with greater mortality compared with that in the general population or even mortality associated with HIV infection. Although liver disease and liver cirrhosis account for the bulk of HCV-related disease burden and deaths, it is becoming increas

Patients with HIV, hepatitis C present unique considerations for cardiologists

The link between CVD (cardiovascular disease) and HIV and hepatitis C virus is complex. Progress has been made in recent years regarding diagnosis and treatment, but unanswered questions remain. Patients with HIV and hepatitis C virus are living longer due to breakthroughs in treatment, leading cardiologists to play a larger role in the associated CVDs that may arise. “The community is learning that HIV-infected individuals are living longer, and because